Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States

Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor... Oncol Ther (2016) 4:189–197 DOI 10.1007/s40487-016-0033-z BRIEF REPORT Real-World Treatment Patterns for Hormone Receptor- Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States Rita Caldeira Mark Scazafave Received: September 5, 2016 / Published online: October 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com Results: Sample sizes ranged from 1272 to 1640 ABSTRACT patients in Europe and from 2225 to 2760 Introduction: Clinical guidelines generally patients in the United States. Across all lines recommend endocrine therapy over of therapy, 37–43% (Europe) and 45–50% chemotherapy for hormone receptor-positive (United States) of patients received advanced breast cancer (unless life-threatening chemotherapy. More patients received metastases are present). This study aimed to endocrine therapy than chemotherapy as assess the real-world treatment patterns of first-line treatment for advanced breast cancer patients with hormone receptor-positive (Europe: 51–54% vs. 33–35%; United States: advanced breast cancer in Europe and the 53–60% vs. 34–42%). In contrast, endocrine United States. therapy-only regimens were given less Methods: Treatment patterns in Europe commonly than chemotherapy-only regimens (France, Germany, Italy, Spain, and the UK) in the third-line setting in both Europe and the and the United States from January 2012 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States

Caldeira, Rita; Scazafave, Mark
Oncology and Therapy , Volume 4 (2) – Oct 27, 2016
Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/real-world-treatment-patterns-for-hormone-receptor-positive-human-xPi1PEw9P6
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0033-z
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:189–197 DOI 10.1007/s40487-016-0033-z BRIEF REPORT Real-World Treatment Patterns for Hormone Receptor- Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States Rita Caldeira Mark Scazafave Received: September 5, 2016 / Published online: October 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com Results: Sample sizes ranged from 1272 to 1640 ABSTRACT patients in Europe and from 2225 to 2760 Introduction: Clinical guidelines generally patients in the United States. Across all lines recommend endocrine therapy over of therapy, 37–43% (Europe) and 45–50% chemotherapy for hormone receptor-positive (United States) of patients received advanced breast cancer (unless life-threatening chemotherapy. More patients received metastases are present). This study aimed to endocrine therapy than chemotherapy as assess the real-world treatment patterns of first-line treatment for advanced breast cancer patients with hormone receptor-positive (Europe: 51–54% vs. 33–35%; United States: advanced breast cancer in Europe and the 53–60% vs. 34–42%). In contrast, endocrine United States. therapy-only regimens were given less Methods: Treatment patterns in Europe commonly than chemotherapy-only regimens (France, Germany, Italy, Spain, and the UK) in the third-line setting in both Europe and the and the United States from January 2012

Journal

Oncology and Therapy – Springer Journals

Published: Oct 27, 2016

References

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
    Cardoso, F; Costa, A; Norton, L
  • The development of endocrine therapy for women with breast cancer
    Sainsbury, R
  • Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012
    Swallow, E; Zhang, J; Thomason, D; Tan, RD; Kageleiry, A; Signorovitch, J
  • Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer
    Andre, F; Neven, P; Marinsek, N
  • Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010)
    Macalalad, AR; Hao, Y; Lin, PL